OncoMatch/Clinical Trials/NCT05092373
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Is NCT05092373 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Atezolizumab and Cabozantinib S-malate for advanced breast carcinoma.
Treatment: Atezolizumab · Cabozantinib S-malate · Nab-paclitaxel — This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the abdomen or thorax that have spread to other parts of the body (advanced). Tumor treating fields therapy on this study utilizes NovoTTF systems that are wearable devices that use electrical fields at different frequencies that may help stop the growth of tumor cells by interrupting cancer cells' ability to divide. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tumor treating fields therapy in combination with either cabozantinib, or with nab-paclitaxel and atezolizumab may help control advanced solid tumors involving the abdomen or thorax.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Endometrial Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Renal Cell Carcinoma
Tumor Agnostic
Disease stage
Metastatic disease required
advanced/metastatic solid cancer ... involving the abdomen or thorax
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anticancer therapy
Exception: Participants who are already on cabozantinib and have progressive disease are allowed to transition to treatment with tumor treating fields and cabozantinib. Participants in both cohorts who already started treatments as standard of care (Cohort 1: Cabozantinib and Cohort 2: nab-paclitaxel and Pembrolizumab) are allowed to start on protocol within the first 2-3 weeks of treatment initiation. Palliative radiation therapy is allowed.
Participants must not receive prior anticancer therapy or radiation therapy within 2 weeks and must not undergo major surgery within 4 weeks prior to initiation of treatment on protocol.
Lab requirements
Blood counts
absolute neutrophil count ≥1,000/µL; platelets ≥75,000/µL; hemoglobin ≥8 g/dL
Kidney function
serum creatinine clearance ≥50 mL/min by Cockcroft-Gault formula
Liver function
total bilirubin level ≤1.5 x ULN (unless Gilbert's syndrome), ALT/SGPT ≤2.5 x ULN (≤5 x ULN with liver metastases)
Normal bone marrow function, defined as absolute neutrophil count ≥1,000/µL; platelets ≥75,000/µL; hemoglobin ≥8 g/dL. Adequate hepatic function as defined by a total bilirubin level ≤1.5 x ULN (unless the patient has known Gilbert's syndrome), and ALT/SGPT ≤2.5 x ULN (≤5 x ULN with liver metastases). Serum creatinine clearance ≥50 mL/min by the Cockcroft-Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify